Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07372989 · ClinicalTrials.gov registry record · Phase 1
Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease
A Phase 1 study of Lung Diseases, Interstitial, sponsored by Maule Stem Cell Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07372989 is a Phase 1 study of Lung Diseases, Interstitial that is actively recruiting participants, run by Maule Stem Cell Research Institute. The registered enrollment target is 50 participants, below the 12,504-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07372989, a Phase 1 study of Lung Diseases, Interstitial, is actively recruiting participants, sponsored by Maule Stem Cell Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I, pilot clinical trial designed to evaluate the safety and exploratory efficacy of nebulized diluted amniotic fluid, Matrix (HAF-Matrix) in adults with interstitial lung disease (ILD). ILDs are progressive fibrotic disorders characterized by aberrant wound-healing responses, chronic inflammation, and dysregulated fibroblast activation, ultimately leading to impaired gas exchange and respiratory failure. Current treatments, such as antifibrotic agents (pirfenidone and nintedanib), slow disease progression but do not reverse existing fibrosis or restore lung function. This pilot study will generate critical safety and preliminary efficacy data to inform future larger-scale trials and optimize dosing strategies for nebulized HAF-based therapeutics in ILD.
Conditions Studied
Interventions
- BIOLOGICAL Matrix
Study Locations (1)
Florida
- Maule Stem Cell Research Institute - Venice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-02 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07372989
The ClinicalTrials.gov registry entry for NCT07372989 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,504-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (100% lower). The listed sponsor is Maule Stem Cell Research Institute, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Diseases, Interstitial appearing as the primary indexed condition, and to 1 intervention - of which Matrix is the first listed.
NCT07372989 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07372989 about?
NCT07372989 is a clinical study titled "Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease". This is a Phase I, pilot clinical trial designed to evaluate the safety and exploratory efficacy of nebulized diluted amniotic fluid, Matrix (HAF-Matrix) in adults with interstitial lung disease (ILD). ILDs are progressive fibrotic disorders characterized by aberrant wound-healing responses, chronic...
What is the current status of trial NCT07372989?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-02. Estimated completion is 2028-10-01.
What conditions does trial NCT07372989 study?
This clinical trial studies the following conditions: Lung Diseases, Interstitial.
What interventions are being tested in trial NCT07372989?
The interventions under investigation include: Matrix (BIOLOGICAL).
Who is sponsoring clinical trial NCT07372989?
This trial is sponsored by Maule Stem Cell Research Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07372989 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases, Interstitial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RECRUITING · Phase 3
-
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
RECRUITING
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
-
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
RECRUITING · NA
-
Cough Capture as a Portal Into the Lung
RECRUITING
-
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.